Moderna Stock Rises 8% in Five Sessions as CEO Sees Cancer Vaccine Working in “More Cancers Than Melanoma”

Key TakeawaysModerna (MRNA)stock gained approximately 8% over five trading sessions through November 5, closing at $241 as investors reassessed its personalized cancer vaccine. Merck (MRK) and Moderna reported that intismeran combined with Keytruda reduced the risk of melanoma recurrence or death by 42%, with a 58% reduction after six months in a prespecified sensitivity analysis.